SEARCH

SEARCH BY CITATION

References

  • 1
    Seeff LB. Natural history of hepatitis C. HEPATOLOGY 1997; 26( Suppl): 21S28S.
  • 2
    Alter MJ: Epidemiology of hepatitis C. HEPATOLOGY 1997; 26( Suppl): 62S65S.
  • 3
    Dienstag JL. The natural history of chronic hepatitis C and what we should do about it. Gastrenterology 1997; 112: 651655.
  • 4
    Afdhal NH. The natural history of hepatitis C. Semin Liver Dis. 2004; 24( Suppl 2): 38.
  • 5
    Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, et al. Host genetic factors influence disease progression in chronic hepatitis C. HEPATOLOGY 2000; 31: 828833.
  • 6
    Allory Y, Charlotte F, Benhamou Y, Opolon P, Le Charpentier Y, Poynard T. Impact of human immunodeficiency virus infection on the histological features of chronic hepatitis C: a case-control study. The MULTIVIRC group. Hum Pathol 2000; 31: 6974.
  • 7
    Pontisso P, Gerotto M, Benvegnu L, Chemello L, Alberti A. Coinfection by hepatitis B virus and hepatitis C virus. Antivir Ther 1998; 3: 137142.
  • 8
    Kamal SM, Madwar MA, Bianchi L, EL Tawil A, Fawzy R, Peters T, et al. Clinical, virological and histopathological features: long-term follow-up in patients with chronic hepatitis C co-infected with Schistosoma mansoni. Liver 2000; 20: 281289.
  • 9
    Kamal SM, Rasenack JW, Bianchi L, Al Tawil A, El Sayed Khalifa K, Peter T, Mansour H, et al. Acute hepatitis C without and with schistosomiasis: correlation with hepatitis C-specific CD4 (+) T-cell and cytokine response. Gastroenterology. 2001; 121: 646656.
  • 10
    Kamal SM, Graham CS, He Q, Bianchi L, Tawil AA, Rasenack JW, et al. Kinetics of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses in HCV and Schistosoma mansoni coinfection: relation to progression of liver fibrosis. J Infect Dis 2004; 189: 11401150.
  • 11
    Armendariz-Borunda J, Katayama K, Seyer JM. Transcriptional mechanisms of type 1 collagen gene expression are differentially regulated by interleukin-1 beta, tumor necrosis factor alpha, and transforming growth factor beta in Ito cells. J Biol Chem 1992; 267: 1431614321.
  • 12
    Bissell DM, Wang SS, Jarnagin WR, Roll FJ. Cell-specific expression of transforming growth factor-beta in rat liver: evidence for autocrine regulation of hepatocyte proliferation. J Clin Invest 1995; 96: 447455.
  • 13
    Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, et al. Host genetic factors influence disease progression in chronic hepatitis C. HEPATOLOGY 2000; 31: 828833.
  • 14
    Olaso E, Friedman S. Molecular regulation of hepatic fibrogenesis. J Hepatol 1998; 29: 836847.
  • 15
    Bain VG, Bonacini M, Govindarajan S, Ma M, Sherman M, Gibas A, et al. A multicentre study of the usefulness of liver biopsy in hepatitis C. J Viral Hepatol 2004; 11: 375382.
  • 16
    Plebani M, Burlina A. Biochemical markers of hepatic fibrosis. Clin Biochem 1991; 24: 219239.
  • 17
    Afdhal NH, Keaveny AP, Cohen SB, et al. Urinary assays for desmosine and hydroxylysylpyridinoline in the detection of cirrhosis. J Hepatol 1997; 27: 9931002.
  • 18
    Murawaki Y, Ikuta Y, Koda M, Kawasaki H. Serum type III procollagen peptide, type IV collagen 7S domain, central triple-helix of type IV collagen and tissue inhibitor of metalloproteinases in patients with chronic viral liver disease: relationship to liver histology. HEPATOLOGY 1994; 20: 780787.
  • 19
    Jeffers LJ, Coelho-Little ME, Cheinquer H, Vargas C, Civantos F, Alvarez L, et al. Procollagen-III peptide and chronic viral C hepatitis. Am J Gastroenterol 1995; 90: 14371440.
  • 20
    Murawaki Y, Yamamoto H, Kawasaki H, Shima H. Serum tissue inhibitor of metalloproteinases in patients with chronic liver disease and with hepatocellular carcinoma. Clin Chim Acta 1993; 218: 4758.
  • 21
    Walsh KM, Timms P, Campbell S, MacSween RN, Morris AJ. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases-1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Dig Dis Sci 1999; 44: 624630.
  • 22
    Murawaki Y, Nishimura Y, Ikuta Y, Idobe Y, Kitamura Y, Kawasaki H. Plasma transforming growth factor-beta 1 concentrations in patients with chronic viral hepatitis. J Gastroenterol Hepatol 1998; 13: 680684.
  • 23
    Gabrielli GB, Capra F, Casaril M, Squarzoni S, Tognella P, Dagradi R, et al. Serum laminin and type III procollagen in chronic hepatitis C. Diagnostic value in the assessment of disease activity and fibrosis. Clin Chim Acta 1997; 265: 2131.
  • 24
    Pares A, Deulofeu R, Gimenez A, Caballeria L, Bruguera M, Caballeria J, et al. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis. HEPATOLOGY 1996; 24: 13991403.
  • 25
    Murawaki Y, Nishimura Y, Ikuta Y, Idobe Y, Kitamura Y, Kawasaki H. Plasma transforming growth factor-beta 1 concentrations in patients with chronic viral hepatitis. J Gastroenterol Hepatol 1998; 13: 680684.
  • 26
    Tsai JF, Jeng JE, Chuang LY, Chang WY, Tsai JH. Urinary transforming growth factor beta1 levels in hepatitis C virus- related chronic liver disease: correlation between high levels and severity of disease. HEPATOLOGY 1997; 25: 11411146.
  • 27
    Nunes DP, Offner GD, Keaveny A, Maldonado N, O'Brien M, Afdhal NH. YKL-40: a new non-invasive serum marker for the assessment of hepatitis C associated liver fibrosis; comparison to hyaluronic acid and procollagen III N peptide levels [Abstract]. HEPATOLOGY 1998: 28( Suppl); 364A.
  • 28
    Johansen JS, Moller S, Price PA, et al. Plasma YKL-40: a new potential marker of fibrosis in patients with alcoholic cirrhosis? Scand J Gastroenterol 1997; 32: 58290.
  • 29
    Johansen JS, Christoffersen P. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 2000; 32: 911920.
  • 30
    Johansen JS, Jensen HS. A new biochemical marker for joint injury: analysis of YKL-40 in serum and synovial fluid. Br J Rheumatol 1993; 32: 949955.
  • 31
    Warren K. Blood flukes (schistosomes) and liver flukes. In: McIntyreN, BenhamouJP, BircherJ, RizzettoM, RhodesJ, eds. Oxford Textbook of Clinical Hepatology. New York: Oxford University Press, 1991: 714721.
  • 32
    Capron A, Dessaint JP. Immunologic aspects of schistosomiasis. Annu Rev Med 1992; 43: 209218.
  • 33
    Angelico M, Renganathan E, Gandin C, Fathy M, Profili MC, Refai W, et al. Chronic liver disease in Alexandria governorate, Egypt: contribution of schistosomiasis and hepatitis virus infections. J Hepatol 1997; 26: 236243.
  • 34
    Pereira LM, Melo MC, Saleh MG, Massarolo P, Koskinas J, Domingues AL, et al. Hepatitis C virus infection in Schistosomiasis mansoni in Brazil. J Med Virol 1995; 45: 423428.
  • 35
    Kamal S, Madwar M, Bianchi L, Tawil AE, Fawzy R, Peters T, et al. Clinical, virological and histopathological features: long-term follow-up in patients with chronic hepatitis C co-infected with S. mansoni. Liver 2000; 20: 281289.
  • 36
    Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696699.
  • 37
    Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with hepatitis C. Lancet 1997; 349: 825832.
  • 38
    Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. HEPATOLOGY 2003; 38: 481492.
  • 39
    Kojima H, Hongo Y, Harada H, Inoue T, Miyaji K, Kashiwagi M, et al. Long-term histological prognosis and serum fibrosis markers in chronic hepatitis C patients treated with interferon. J Gastroenterol Hepatol 2001; 16: 10151021.
  • 40
    Schuppan D. Connective tissue polypeptides in serum; new parameters of connective tissue synthesis and degradation in liver fibrosis. Z Gastroenterol 1992; 30: 2934.
  • 41
    Nojgaard C, Johansen JS, Christensen E, Skovgaard LT, Price PA, Becker U, et al. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol 2003; 39: 179186.